The Global Neurodiagnostics Market is Estimated to Witness High Growth Owing to Technological Advancements in Imaging

Neurodiagnostics refers to the
diagnostic testing performed to help diagnose neurological disorders and
diseases related to the central and peripheral nervous systems. These tests aid
in evaluating the neurological functioning, neuroanatomical structure, and
identifying injuries or defects in the nervous system. Neurodiagnostics
includes imaging tests such as computed tomography (CT) scans, magnetic
resonance imaging (MRI), electroencephalography (EEG), and lumbar puncture.
Advancements in imaging technologies and identification of new biomarkers have
improved the detection of neurological conditions.



The Global Neurodiagnostics Market is
estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR
of 8.1% over the forecast period 2024 To 2031.

Rising geriatric population and the
subsequent increase in neurological disorders, technological advancements in
diagnostic imaging techniques, and growing awareness about early disease
diagnosis are fueling market growth.



Key Takeaways

Key players operating in the Neurodiagnostics Market are Koninklijke Philips
N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings
Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon
Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus
Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro,
NEUROLITE AG, and Atlantic Health System.



Key Neurodiagnostics
Market Demand include rising need for non-invasive diagnostic
techniques, untapped potential in emerging economies, and growing demand for
integrated diagnostic platforms. Advancing technologies in neuroimaging such as
high-resolution MRI, multi-parametric MRI, magnetic resonance spectroscopy, and
amyloid and tau positron emission tomography (PET) have improved diagnostic
accuracy.



Market drivers:

The growing geriatric population is the primary driver for the neurodiagnostics
market. The risk of neurological disorders substantially increases with age. As
per the United Nations, the world’s population aged 60 years and above is
expected to double from 12% to 22% between 2015 and 2050.

Get More
Insights On, Neurodiagnostics
Market